# GRN-1201

Source: https://onco.cc/drugs/grn-1201/  
OnCo record `grn-1201` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GRN-1201 is an experimental peptide vaccine from BrightPath Biotherapeutics, in phase 2 trials for melanoma and non-small cell lung cancer; its current status is not stated.

## Summary

GRN-1201 is a peptide vaccine (4 peptides) from BrightPath Biotherapeutics. A cancer vaccine made of four peptides, tested in HLA-A*02 patients with resected melanoma and with pembrolizumab in PD-L1-positive metastatic NSCLC. Its furthest stage is phase 2, for melanoma and non-small cell lung cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 in melanoma completed; phase 2 with pembrolizumab in NSCLC terminated ('Recruitment rate too slow'). Not on the company's current pipeline page. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: GRN-1201
- Modality: Peptide vaccine (4 peptides)
- Mechanism: A cancer vaccine made of four peptides, tested in HLA-A*02 patients with resected melanoma and with pembrolizumab in PD-L1-positive metastatic NSCLC.

## Sources

- BrightPath Biotherapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT02696356
- BrightPath Biotherapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT03417882
- BrightPath Biotherapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT03417882
- ClinicalTrials.gov: trials of GRN-1201: https://clinicaltrials.gov/search?intr=GRN-1201

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [BrightPath Biotherapeutics](https://onco.cc/companies/brightpath-biotherapeutics/)
- trials: [GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC](https://onco.cc/trials/nct03417882/), [Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma](https://onco.cc/trials/nct02696356/)

---
JSON: https://onco.cc/api/v1/entities/grn-1201.json